Ashraf Henry, MD
Pain Medicine · Amherst, NYNPI 1033147400
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.9% of the total across 736 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 60 manufacturers, the largest accounting for just 11.1% — the pattern of someone who eats at a lot of different presentations.
Across 736 payments — averaging $17.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Collegium Pharmaceutical, Inc.$1K
- Nevro Corp.$1K
- AbbVie$1K
- SK Life Science, Inc.$885
- Abbott$855
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$828
- plus $7K from 54 others
Across 5 payments — averaging $30,923 each. An ownership or investment interest held by the physician or an immediate family member.
- Neurology Practice Consortium GPO, LLC$155K
What the payments were for
- Food & beverage$13,196100%
- Education$80%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$13,204 in reported general payments places this provider in the 85th percentile of 503 pain medicine providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ZtlidoLidocaine | 96 | $64,073 |
| RelistorMethylnaltrexone Bromide | 16 | $63,653 |
| PercocetOxycodone Hcl/Acetaminophen | 11 | $58,051 |
| OxycontinOxycodone Hcl | 80 | $51,597 |
| BelbucaBuprenorphine Hcl | 48 | $37,721 |
| Buprenorphine | 146 | $36,890 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 1,185 | $35,581 |
| Xtampza ErOxycodone Myristate | 45 | $31,394 |
| NucyntaTapentadol Hcl | 27 | $25,646 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 502 | $18,371 |
| Nucynta ErTapentadol Hcl | 12 | $11,760 |
| Oxymorphone Hcl ErOxymorphone Hcl | 20 | $11,567 |
| Lidocaine | 99 | $10,567 |
| Oxycodone Hcl | 468 | $9,801 |
| Pregabalin | 400 | $9,481 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Collegium Pharmaceutical, Inc.Belbuca, Xtampza Er, Nucynta, Nucynta Er | $1,464 | $106,521132 claims |
| Scilex Pharmaceuticals Inc.Ztlido | $474 | $64,07396 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCRelistor | $828 | $63,65316 claims |
| AbbVieSavella | $1,127 | $6,73814 claims |
| Redhill Biopharma Inc.Movantik | $86 | $6,68217 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 503 pain medicine providers in New York.
Other pain medicine in Amherst
- Gary SchwartzBrooklyn$756K
- Amitabh GulatiNew York$614K
- William CaldwellStony Brook$530K
- Brian DurkinPort Jefferson$455K
- David SpinnerNew York$391K
- Grace FordeNew Hyde Park$355K
- Romanth WaghmaraeHamburg$158K
- Samuel BrownSouthold$147K
- Fred CohenBronx$141K
- Eric LeeNew York$117K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.